USA – Amber Implants, a The Hague, Netherlands-based innovative medical technology company developing next generation spinal implants for spinal injuries, closed its US$10m Series A Financing.
The round was co-led by the founders and existing venture capital investors, with participation from angel investors and non-dilutive government funding.The company intends to use the funds to advance its vertebral body augmentation system, VCFix®, through all preclinical verification and validation tests, ISO 13485 certification, regulatory activities, and an early feasibility clinical study and a pilot and pivotal clinical trial.Founded in 2018 by Dr. Banafsheh Sajadi, Chief Executive Officer, Amber Implants is a medical technology startup located in the Netherlands and United States which has developed spinal implants for Vertebral Compression Fractures (VCF), and is focused on improving patient outcomes through implants that provide more natural healing and stability. In September 2021, the company was granted Breakthrough Device Designation for its VCFix® spinal system by the US Food and Drug Administration (FDA), which enables direct and interactive communications with the US FDA and priority review. Amber Implants will also have more flexibility with regards to clinical studies, a dedicated team for reviewing the application, and reimbursement through Medicare for four years.20/01/2022
